#China #Cambridge #nanomedicine #METiS Technologies #AiLNP

METiS Technologies Presents Innovative AI-Driven Nanodelivery Platform

At the recently concluded 2025 Controlled Release Society (CRS) Annual Meeting, METiS Technologies captivated attendees with its pioneering research on AI-powered lipid nanoparticle delivery systems. The meeting is a significant stage in the field of drug delivery and is renowned as the leading scientific forum for advancements in this area.

Breakthroughs in Nanomedicine

Held in Cambridge, Massachusetts, this year’s conference saw METiS Technologies stand out as the sole representative from China to deliver a poster presentation showcasing its proprietary AiLNP platform. Dr. Hongming Chen, the co-founder and Chief RD Officer of METiS, along with Dr. Andong Liu, Vice President, introduced a poster titled “AI-Empowered LNP Discovery for Organ-Targeted RNA Delivery” which highlighted their latest findings.

The AiLNP platform represents a leap forward in the applications of Artificial Intelligence within the biotechnology realm. By utilizing a unique combination of a lipid generation model, high-throughput microfluidics for LNP assembly, and an extensive proprietary lipid library, METiS has expanded the nanomaterial design possibilities by over 1,000-fold when compared to conventional methodologies.

Redefining Efficiency and Specificity

The crux of METiS Technologies’ showcase was their ability to rapidly design and optimize tissue-targeted lipid nanoparticles (LNPs) that promise enhanced drug delivery. These advancements not only increase delivery efficiency but also specificity when targeting specific tissues, which is paramount in achieving effective medical treatments.

A particular highlight was the presentation of muscle-targeted LNPs which were shown to successfully deliver genetic material for gene editing in both skeletal and cardiac muscles. The use of CRISPR-Cas9 technology in experiments indicated that these LNPs could reduce serum TTR levels by approximately 90% with minimal adverse effects in non-human primates. This marks a significant step forward in gene editing potential.

Expanding Horizons in Drug Delivery

Through predictive AI models and simulations of molecular dynamics, the AiLNP platform also allows METiS to gain mechanistic insights into lipid behavior, predicting multiple physicochemical parameters that are critical for the development of high-performance delivery systems. The findings at the conference underscored the importance of speeding up the design and discovery processes for LNPs aimed at various tissues, indicating a strong future for the platform.

Not only are liver-targeted LNPs achieving best-in-class performance for gene editing, but pulmonary-targeted LNPs are exhibiting commendable delivery efficiency and specificity. The translation of these results from rodents to non-human primates was particularly noteworthy, supporting future applications in durable genetic corrections across species.

A Vision for the Future

Dr. Chris Lai, co-founder and CEO of METiS Technologies, emphasized the company's commitment to leading globally in the realm of AI-driven nanodelivery solutions. He remarked that effective nanodelivery systems are crucial for the next generation of programmable medicines and that AI will play a vital role in facilitating this evolution.

As METiS Technologies continues to innovate at the intersection of artificial intelligence and nanomaterial science, they remain dedicated to exploring new therapeutic avenues for myriad diseases, ranging from cancer to neurodegenerative disorders. Their work aims not only to innovate drug delivery but to enhance patient health on a broader scale.

With a firm resolve to address long-standing challenges in nanomaterial design and application, METiS Technologies is poised to spearhead advancements in healthcare that could reshape treatment protocols across the globe.

In closing, the 2025 CRS Annual Meeting served as a pivotal platform for METiS to present its transformative visions for nanomedicine, reinforcing its role at the forefront of AI-enhanced drug delivery systems.